Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: A retrospective immunohistochemical study

Partha S. Ray, Sanjay P. Bagaria, Jinhua Wang, Jaime M. Shamonki, Xing Ye, Myung Shin Sim, Shawn Steen, Ying Qu, Xiaojiang Cui, Armando E. Giuliano

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Basal-like breast cancer (BLBC) has a poor prognosis and is often identified by the triple-negative phenotype (TNP) and/or basal cytokeratins (CKs). Overexpression of mRNA for forkhead box C1 (FOXC1) transcription factor was recently identified as a pivotal prognostic biomarker of BLBC. We investigated the prognostic value of FOXC1 protein expression in invasive breast cancer and compared its prognostic significance to that of TNP and basal CKs. Methods: Archived TNP specimens of primary invasive ductal breast cancer from 759 patients were examined by immunohistochemical staining for FOXC1, CK5/6, and CK14; prognostic significance was assessed using multivariate analyses. In addition, the impact of adding FOXC1 versus basal CKs to TNP-based BLBC assessment was assessed. Results: FOXC1 protein expression was a significant predictor of overall survival on univariate (hazard ratio [HR] 3.364 95% confidence interval [CI] 1.758-6.438, P = 0.0002) and multivariate (HR 3.389 95% CI 1.928-7.645, P = 0.0001) analyses, despite its correlation with younger age (P = 0.0003). Interestingly, nodal status was not significant on multivariate analysis when FOXC1 expression status was included in the analysis. BLBC defined by TNP plus FOXC1 demonstrated superior prognostic relevance compared to BLBC defined by TNP or TNP plus basal CKs. Conclusions: Immunohistochemical detection of FOXC1 expression in TNP invasive breast cancer is an independent prognostic indicator that is superior to conventional immunohistochemical surrogates of BLBC. Prospective validation is warranted to further define the diagnostic, prognostic, and predictive utility of FOXC1 in breast cancer management and clinical trial design.

Original languageEnglish (US)
Pages (from-to)3839-3847
Number of pages9
JournalAnnals of Surgical Oncology
Volume18
Issue number13
DOIs
StatePublished - Dec 2011
Externally publishedYes

Fingerprint

Retrospective Studies
Breast Neoplasms
Phenotype
Keratins
Forkhead Transcription Factors
Triple Negative Breast Neoplasms
Multivariate Analysis
Confidence Intervals
Biomarkers
Clinical Trials
Staining and Labeling
Messenger RNA
Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value : A retrospective immunohistochemical study. / Ray, Partha S.; Bagaria, Sanjay P.; Wang, Jinhua; Shamonki, Jaime M.; Ye, Xing; Sim, Myung Shin; Steen, Shawn; Qu, Ying; Cui, Xiaojiang; Giuliano, Armando E.

In: Annals of Surgical Oncology, Vol. 18, No. 13, 12.2011, p. 3839-3847.

Research output: Contribution to journalArticle

Ray, PS, Bagaria, SP, Wang, J, Shamonki, JM, Ye, X, Sim, MS, Steen, S, Qu, Y, Cui, X & Giuliano, AE 2011, 'Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: A retrospective immunohistochemical study', Annals of Surgical Oncology, vol. 18, no. 13, pp. 3839-3847. https://doi.org/10.1245/s10434-011-1657-8
Ray, Partha S. ; Bagaria, Sanjay P. ; Wang, Jinhua ; Shamonki, Jaime M. ; Ye, Xing ; Sim, Myung Shin ; Steen, Shawn ; Qu, Ying ; Cui, Xiaojiang ; Giuliano, Armando E. / Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value : A retrospective immunohistochemical study. In: Annals of Surgical Oncology. 2011 ; Vol. 18, No. 13. pp. 3839-3847.
@article{aa14d626f8de4cb09428d97682ed37f5,
title = "Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: A retrospective immunohistochemical study",
abstract = "Background: Basal-like breast cancer (BLBC) has a poor prognosis and is often identified by the triple-negative phenotype (TNP) and/or basal cytokeratins (CKs). Overexpression of mRNA for forkhead box C1 (FOXC1) transcription factor was recently identified as a pivotal prognostic biomarker of BLBC. We investigated the prognostic value of FOXC1 protein expression in invasive breast cancer and compared its prognostic significance to that of TNP and basal CKs. Methods: Archived TNP specimens of primary invasive ductal breast cancer from 759 patients were examined by immunohistochemical staining for FOXC1, CK5/6, and CK14; prognostic significance was assessed using multivariate analyses. In addition, the impact of adding FOXC1 versus basal CKs to TNP-based BLBC assessment was assessed. Results: FOXC1 protein expression was a significant predictor of overall survival on univariate (hazard ratio [HR] 3.364 95{\%} confidence interval [CI] 1.758-6.438, P = 0.0002) and multivariate (HR 3.389 95{\%} CI 1.928-7.645, P = 0.0001) analyses, despite its correlation with younger age (P = 0.0003). Interestingly, nodal status was not significant on multivariate analysis when FOXC1 expression status was included in the analysis. BLBC defined by TNP plus FOXC1 demonstrated superior prognostic relevance compared to BLBC defined by TNP or TNP plus basal CKs. Conclusions: Immunohistochemical detection of FOXC1 expression in TNP invasive breast cancer is an independent prognostic indicator that is superior to conventional immunohistochemical surrogates of BLBC. Prospective validation is warranted to further define the diagnostic, prognostic, and predictive utility of FOXC1 in breast cancer management and clinical trial design.",
author = "Ray, {Partha S.} and Bagaria, {Sanjay P.} and Jinhua Wang and Shamonki, {Jaime M.} and Xing Ye and Sim, {Myung Shin} and Shawn Steen and Ying Qu and Xiaojiang Cui and Giuliano, {Armando E.}",
year = "2011",
month = "12",
doi = "10.1245/s10434-011-1657-8",
language = "English (US)",
volume = "18",
pages = "3839--3847",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "13",

}

TY - JOUR

T1 - Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value

T2 - A retrospective immunohistochemical study

AU - Ray, Partha S.

AU - Bagaria, Sanjay P.

AU - Wang, Jinhua

AU - Shamonki, Jaime M.

AU - Ye, Xing

AU - Sim, Myung Shin

AU - Steen, Shawn

AU - Qu, Ying

AU - Cui, Xiaojiang

AU - Giuliano, Armando E.

PY - 2011/12

Y1 - 2011/12

N2 - Background: Basal-like breast cancer (BLBC) has a poor prognosis and is often identified by the triple-negative phenotype (TNP) and/or basal cytokeratins (CKs). Overexpression of mRNA for forkhead box C1 (FOXC1) transcription factor was recently identified as a pivotal prognostic biomarker of BLBC. We investigated the prognostic value of FOXC1 protein expression in invasive breast cancer and compared its prognostic significance to that of TNP and basal CKs. Methods: Archived TNP specimens of primary invasive ductal breast cancer from 759 patients were examined by immunohistochemical staining for FOXC1, CK5/6, and CK14; prognostic significance was assessed using multivariate analyses. In addition, the impact of adding FOXC1 versus basal CKs to TNP-based BLBC assessment was assessed. Results: FOXC1 protein expression was a significant predictor of overall survival on univariate (hazard ratio [HR] 3.364 95% confidence interval [CI] 1.758-6.438, P = 0.0002) and multivariate (HR 3.389 95% CI 1.928-7.645, P = 0.0001) analyses, despite its correlation with younger age (P = 0.0003). Interestingly, nodal status was not significant on multivariate analysis when FOXC1 expression status was included in the analysis. BLBC defined by TNP plus FOXC1 demonstrated superior prognostic relevance compared to BLBC defined by TNP or TNP plus basal CKs. Conclusions: Immunohistochemical detection of FOXC1 expression in TNP invasive breast cancer is an independent prognostic indicator that is superior to conventional immunohistochemical surrogates of BLBC. Prospective validation is warranted to further define the diagnostic, prognostic, and predictive utility of FOXC1 in breast cancer management and clinical trial design.

AB - Background: Basal-like breast cancer (BLBC) has a poor prognosis and is often identified by the triple-negative phenotype (TNP) and/or basal cytokeratins (CKs). Overexpression of mRNA for forkhead box C1 (FOXC1) transcription factor was recently identified as a pivotal prognostic biomarker of BLBC. We investigated the prognostic value of FOXC1 protein expression in invasive breast cancer and compared its prognostic significance to that of TNP and basal CKs. Methods: Archived TNP specimens of primary invasive ductal breast cancer from 759 patients were examined by immunohistochemical staining for FOXC1, CK5/6, and CK14; prognostic significance was assessed using multivariate analyses. In addition, the impact of adding FOXC1 versus basal CKs to TNP-based BLBC assessment was assessed. Results: FOXC1 protein expression was a significant predictor of overall survival on univariate (hazard ratio [HR] 3.364 95% confidence interval [CI] 1.758-6.438, P = 0.0002) and multivariate (HR 3.389 95% CI 1.928-7.645, P = 0.0001) analyses, despite its correlation with younger age (P = 0.0003). Interestingly, nodal status was not significant on multivariate analysis when FOXC1 expression status was included in the analysis. BLBC defined by TNP plus FOXC1 demonstrated superior prognostic relevance compared to BLBC defined by TNP or TNP plus basal CKs. Conclusions: Immunohistochemical detection of FOXC1 expression in TNP invasive breast cancer is an independent prognostic indicator that is superior to conventional immunohistochemical surrogates of BLBC. Prospective validation is warranted to further define the diagnostic, prognostic, and predictive utility of FOXC1 in breast cancer management and clinical trial design.

UR - http://www.scopus.com/inward/record.url?scp=82955236210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955236210&partnerID=8YFLogxK

U2 - 10.1245/s10434-011-1657-8

DO - 10.1245/s10434-011-1657-8

M3 - Article

C2 - 21424368

AN - SCOPUS:82955236210

VL - 18

SP - 3839

EP - 3847

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 13

ER -